A breast cancer drug from AstraZeneca and Daiichi Sankyo now has FDA approval to address a brand new category of the disease, a decision that enables the targeted therapy to reach a much broader patient population. The drug, Enhertu, was initially approved to address cancers characterized by the abundance of a protein called HER2. The drug made waves in […]
